BOVNF (BioInvent International AB) Quality Rank


BOVNF BioInvent International AB BOVNF
51 GF Score
Price $3.29
GF Value $6.38
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

BioInvent International AB Quality Rank Related Terms

BOVNF
51GF Score
BioInvent International AB BOVNF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioInvent International AB (BOVNF) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of $3.29 is trading 48.5% below its estimated GF Value™ of $6.38.

Key valuation signals for BOVNF:

  • Quality Rank:
  • GF Value™: $6.38 vs. price of $3.29 (48.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
51GF Score

Get the complete analysis for BOVNF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$6.38
GF Value